Click Here to
News, Updates,
& More
Stay Up
to Date

JHOP - February 2020 Vol 10, No 1

A new CD45-targeting antibody radiation-conjugate, iodine-131 (I-131) apamistamab, may be a less toxic alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens before initiation of adoptive cell therapy, according to results presented at ASH 2019.
New data presented at ASH 2019 show that mosunetuzumab holds promise as a durable and safe treatment for patients with treatment-refractory non-Hodgkin lymphoma (NHL), including those whose disease progressed after receiving chimeric antigen receptor (CAR) T-cell therapy. In a phase 1/1b clinical trial, the novel BiTE mosunetuzumab achieved durable responses in patients with refractory NHL, including complete remissions in 22.2% of patients who had previously received CAR T-cell therapy.
This section provides a brief overview of new cancer drugs or new indications approved by the FDA between December 16, 2019, and January 23, 2020.

In the United States, colorectal cancer (CRC) is the third most common cancer type and the second most common cause of cancer mortality.1,2 The lethal nature of CRC is attributable to being largely asymptomatic until advanced stages and the lack of curative treatment options for patients with advanced-stage disease.3 CRC screening in the average-risk population has clear, early detection and mortality benefits.1-3 Recently, not being up to date with screening for CRC was associated with an approximate 3-fold risk for CRC-related mortality.4

Clostridium difficile–related diarrhea is one of the most common types of nosocomial diarrhea in the United States, with an incidence of 15% to 25%.1 Infectious diarrhea resulting from C difficile is a common complication in patients undergoing hematopoietic stem-cell transplant (HSCT), with higher rates in those undergoing allogeneic than autologous HSCT (12%-18% vs 6%-8.5%, respectively).2-4

Scleroderma is a condition in which chronic inflammation and immune effects in the tissue lead to fibrotic changes caused by excess collagen and potentially vascular damage in the skin.1,2 These immunologic changes lead to a hardening and thickening of various depths of the skin, which may have profound effects on a patient’s quality of life and requires complex medical management.
Granulocyte colony-stimulating factor (G-CSF) is often used after a hematopoietic stem-cell transplant (HSCT) to expedite neutrophil recovery after high-dose chemotherapy. Prolonged neutropenia after HSCT increases the risk for infectious complications and can contribute significantly to morbidity and mortality.1-3
Page 2 of 2
Results 11 - 17 of 17